NCT06091410 - Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

February 25, 2025

Study Completion Date

June 25, 2025

Conditions

COVID-19InfluenzaVaccine ReactionContaminant Injected

Interventions

BIOLOGICAL

Omicron-containing COVID-19 vaccine

The COVID-19 vaccine approved for use in the 2023-2024 season

BIOLOGICAL

influenza vaccine

inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season

Trial Locations (2)

22711

International St. Mary's hospital, Incheon

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors

collaborator

Korea University Guro Hospital

OTHER

lead

Catholic Kwandong University

OTHER